Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| In closing, we have a strong financial position to advance our mission, and we remain committed to developing our HBV assets to provide a functional cure for chronic HBV |
| Last June at EASL, we reported preliminary data that continues to reinforce our confidence in imdusiran's ability to effectively lower surface antigen |
| As we continue to advance the clinical development of imdusiran and AB-101, we believe both compounds are well positioned to deliver on our goal of developing a functional cure for hepatitis B and driving value for our company |
| We believe nivolumab may further boost the host immune response |
| I'm excited for my new role and plan to leverage my extensive scientific, strategic, transactional, and commercial experience with antiviral and infectious disease companies to continue to move Arbutus forward |
| In 2024, our focus is to position Arbutus for continued success and create value for all our stakeholders |
| All of our scientists take great pride in the intellectual property they develop which takes great effort, time, resources, and expense |
| There remains a need for finite and more efficacious HBV treatments that further improve long-term outcomes and increase functional cure rates as fewer than 5% of patients currently achieve functional cure with currently approved nukes or interferon |
| That said, our current strategy is evaluating imdusiran in combination with other agents in multiple Phase 2a clinical trials with the goal of gaining valuable insights on efficacy, safety, and optimal dosing to help inform the design of a Phase 2b clinical trial with imdusiran as the cornerstone therapy |
| As a Co-Founder of Arbutus, I am honored to have this opportunity to lead my colleagues in our mission to develop a functional cure for the millions of people chronically infected with hepatitis B virus |
| We take this, obviously, very seriously, we were pleased with the actual hearing itself, and we look forward to Justice Goldberg's ruling which we expect, as you know, within 60 days of February 8th |
| In 2023, we made several important strategic choices to best position Arbutus for long-term success |
| Importantly, we believe our cash runway is sufficient to fund our operations into the first quarter of 2026 |
| We appreciate everyone's interest |
| Karen? Karen Sims Thanks Mike and good morning everyone |
| Dave? David Hastings Thanks Karen and good morning everybody |
| Good morning everyone and thank you for joining us today |
| And thanks everyone for joining us this morning |
| Dennis Ding Thank you |
| Achieving undetectable surface antigen levels in either of our current Phase 2a clinical trials would certainly be an important validation of imdusiran's role in potentially achieving the functional cure for hepatitis B patients |
| Thanks |
| Thanks |
| Thank you |
| Thank you |
| Thank you |
| Our goal is to develop a treatment for chronic hepatitis B virus patients that results in at least a 20% functional cure rate to address this large unmet medical need |
| Brian Skorney Hey, Good morning |
| Statement |
|---|
Please consider a small donation if you think this website provides you with relevant information